Records containing: Influenza
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2022-03-31A Clinical Trial to Assess Immunogencity and Safety of 2 Doses of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years
-
CLINICAL_TRIALS study record update · 2022-03-28Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA vs. the Vaxigrip® Inactivated Influenza Split Vaccine Manufactured by Sanofi Pasteur, France, in Volunteers Aged 18-60 Years
-
CLINICAL_TRIALS study record update · 2022-03-18Effect of Influenza Vaccination or Infection on the Development of Protective Immunity in Children
-
CLINICAL_TRIALS study record update · 2022-03-18National Vaccine Adverse Event Reporting Survey to Determine the Etiology of Vaccine-Induced Injury
-
CLINICAL_TRIALS study record update · 2022-03-14A Prospective Household Study of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus Community Burden, Transmission Dynamics and Viral Interaction in South Africa (the PHIRST-C Study)
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2022-03-07Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform
-
CLINICAL_TRIALS study record update · 2022-03-04Evaluation of Free Air Portable Air Powered Respirator System for Prevention of Influenza Transmission
-
CLINICAL_TRIALS study record update · 2022-01-26A Phase II Study to Evaluate and Compare the Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered With and Without AS03 Adjuvant and Monovalent Inactivated Influenza A/H3N2v Virus Vaccine Administered Without Adjuvant in Healthy Adults Through Standard and Systems Biology Analyses
-
CLINICAL_TRIALS study record update · 2022-01-25Digital Online Consultations - Effects on Antibiotic Prescribing and Health Care Utilization in Primary Care
-
CLINICAL_TRIALS study record update · 2022-01-19Broadening Our Understanding of Early Versus Late Influenza Vaccine
-
CLINICAL_TRIALS study record update · 2022-01-12A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United States Licensed Quadrivalent Influenza Virus Vaccine (QIV) in Healthy Subjects 6 Months Through 47 Months
-
CLINICAL_TRIALS study record update · 2022-01-06Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years
-
CLINICAL_TRIALS study record update · 2022-01-06Phase I Simple Blind, Placebo Controlled, Randomized Safety and Reactogenicity Trial of the Flu-M Quadro Tetravalent Inactivated Split Influenza Vaccine, Solution for Intramuscular Injection, Produced by FSUE SPbSRIVS FMBA, vs. Placebo in Healthy Volunteers
-
CLINICAL_TRIALS study record update · 2022-01-06Prospective, Multicenter, Double-blind, Randomized, Comparative Immunogenicity and Safety Trial of Flu-M [Inactivated Split Influenza Vaccine], Solution for Intramuscular Injection, 0.5 ml (FSUE SPbSRIVS FMBA), vs. Ultrix®, Solution for Intramuscular Injection, 0.5 ml (FORT LLC) in Volunteers Aged Over 60 Years
-
CLINICAL_TRIALS study record update · 2022-01-03A Phase I Study to Assess the Safety, Reactogenicity and Immunogenicity of Two Quadrivalent Seasonal Influenza Vaccines (Fluzone(R) or Flublok(R)) With or Without One of Two Adjuvants (AF03 or Advax-CpG55.2) in Healthy Adults 18-45 Years of Age
-
CLINICAL_TRIALS study record update · 2021-12-06Kinetics of Mucosal and Systemic Immune Responses to Intranasal Live Attenuated Influenza Vaccine (LAIV)
-
CLINICAL_TRIALS study record update · 2021-11-30A Comparison of CD4 T Cell Induction and Antibody Responses Between a Pure Hemagglutinin Influenza Vaccine and Licensed Subvirion Influenza Vaccine Made in Eggs or Cell Culture in Healthy Adults.
-
CLINICAL_TRIALS study record update · 2021-11-17Improving Influenza Vaccination Delivery Across a Health System by the Electronic Health Records Patient Portal
-
CLINICAL_TRIALS study record update · 2021-11-01A Phase I/II Randomized Trial of the Safety and Immunogenicity of Cold Adapted Influenza Vaccine (FluMist) in HIV-Infected Children and Adolescents
-
CLINICAL_TRIALS study record update · 2021-10-29Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021
-
CLINICAL_TRIALS study record update · 2021-10-27Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Efficacy and Safety of the AV5080 Drug in Patients With Influenza
-
CLINICAL_TRIALS study record update · 2021-10-26Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza
-
CLINICAL_TRIALS study record update · 2021-10-21A Phase I Trial to Evaluate the Safety and Immunogenicity of an Influenza Vaccination Strategy Including a H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-17 Years Old
-
CLINICAL_TRIALS study record update · 2021-09-16A Phase 1, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
-
CLINICAL_TRIALS study record update · 2021-09-13A Pivotal Multi-center, Randomized, Modified Double-blind, Placebo-controlled Phase 3 Trial to Assess the Safety and Clinical Efficacy of M-001 Influenza Vaccine Administered Intra-muscularly Twice in Older Adults and Elderly (≥50 Years).